Today’s announcement opens the possibility of international patent protection for DiviTum outside the breast cancer space, including the market for checkpoint inhibitors. Our view is that this is mainly positive regarding the prospects of securing future CDx (companion diagnostic) collaborations. Biovica has already secured many collaborations in the core Breast Cancer market related to CDK 4/6 space, and this announcement expands the potential market.